Kineta could receive more than $359 million as a result of the deal.
Seattle biotech Kineta will partner with big biotech company Genentech to make and sell a drug used to treat chronic pain, in a deal that could be worth more than $359 million for the Seattle company.
Kineta announced Monday it made a deal with San Francisco-based Genentech to develop Kineta’s existing target therapy into a medicine that treats nerve pain.
“There is a tremendous unmet patient need to develop more effective, safer and nonaddictive therapies for the many people who suffer from chronic pain,” Kineta CEO Shawn Iadonato said in a statement Monday.
The Seattle company will be eligible to receive up to $359 million as part of the deal, in addition to an undisclosed upfront payment. It could also receive royalties on eventual sales of products that result from the deal.
Most Read Business Stories
- Seattle-area home price cool-down stands out among U.S. cities
- Flawed analysis, failed oversight: How Boeing, FAA certified the suspect 737 MAX flight control system | Times Watchdog
- Boeing has 737 MAX software fix ready for airlines as DOT launches new scrutiny of entire FAA certification process
- Belltown penthouse is region’s priciest condo sale ever — and new owners won't even live there
- Amazon finds an alternative workforce through Northwest Center, a Seattle nonprofit helping people with disabilities